Clearmind targets Hong Kong patent protection to support PTSD drug development push - CMND News | RalliesClearmind targets Hong Kong patent protection to support PTSD drug development push
C
CMND• Hong Kong patent filing supports PTSD compound strategy
- Clearmind set plans to expand patent protection in Asia via a Hong Kong filing for novel psychedelic compounds aimed at PTSD.
- Development will advance under its exclusive global license from Yissum, covering development, manufacturing, commercialization, regulatory execution.
- Strategy targets the PTSD therapeutics market, estimated at USD 18.5 billion in 2025, projected at USD 30.2 billion by 2035.
- IP roadmap calls for additional patent filings when warranted, building on 19 patent families with 32 granted patents.
MARA
•
